Table 2 Summary of treatment outcomes

From: PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial

Clinical endpoints

Total (N = 40)

95% CI of percentage

12-week objective response rate, n (%)

16 (40.0)

[24.9–56.7]

Best overall response rate, n (%)

19 (47.5)

[31.5–63.9]

Disease control rate, n (%)

36 (90.0)

[76.3–97.2]

  1. 12-week ORR 12-week objective response rate, refer to the proportion of subjects achieving a complete response (CR) or partial response (PR) at around 12 weeks after first administration of study treatment, CI confidence interval.
Back to article page